163 related articles for article (PubMed ID: 28268139)
1. Discovery of new Syk inhibitors through structure-based virtual screening.
Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study.
Wang X; Guo J; Ning Z; Wu X
Molecules; 2018 Nov; 23(12):. PubMed ID: 30487406
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Kawatkar SP; Barlaam B; Kemmitt P; Simpson I; Watson D; Wang P; Lamont S; Su Q; Boiko S; Ikeda T; Patel J; Pike A; Pollard H; Read J; Sarkar U; Wang H; Wen Q; Yan Z; Dowling JE; Dry H; Edmondson SD
Bioorg Med Chem Lett; 2020 Sep; 30(18):127393. PubMed ID: 32721854
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
[TBL] [Abstract][Full Text] [Related]
5. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
7. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
8. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
[TBL] [Abstract][Full Text] [Related]
9. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
[TBL] [Abstract][Full Text] [Related]
11. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Barker MD; Liddle J; Atkinson FL; Wilson DM; Dickson MC; Ramirez-Molina C; Lewis H; Davis RP; Somers DO; Neu M; Jones E; Watson R
Bioorg Med Chem Lett; 2018 Nov; 28(21):3458-3462. PubMed ID: 30249354
[TBL] [Abstract][Full Text] [Related]
13. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol.
Kaur M; Kumari A; Bahia MS; Silakari O
J Mol Graph Model; 2013 Feb; 39():165-75. PubMed ID: 23280414
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Grimster NP; Gingipalli L; Barlaam B; Su Q; Zheng X; Watson D; Wang H; Simpson I; Pike A; Balazs A; Boiko S; Ikeda TP; Impastato AC; Jones NH; Kawatkar S; Kemmitt P; Lamont S; Patel J; Read J; Sarkar U; Sha L; Tomlinson RC; Wang H; Wilson DM; Zehnder TE; Wang L; Wang P; Goldberg FW; Shao W; Fawell S; Dry H; Dowling JE; Edmondson SD
Bioorg Med Chem Lett; 2020 Oct; 30(19):127433. PubMed ID: 32717371
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.
Chang CF; Lin WH; Ke YY; Lin YS; Wang WC; Chen CH; Kuo PC; Hsu JTA; Uang BJ; Hsieh HP
Eur J Med Chem; 2016 Nov; 124():186-199. PubMed ID: 27573544
[TBL] [Abstract][Full Text] [Related]
18. Identification of natural product-based effective inhibitors of spleen tyrosine kinase (SYK) through virtual screening and molecular dynamics simulation approaches.
Ali T; Anjum F; Choudhury A; Shafie A; Ashour AA; Almalki A; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2024 Apr; 42(7):3459-3471. PubMed ID: 37261484
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis.
Li X; Huang Y; Cheng J; Zhang L; Mao F; Zhu J; Sheng C; Li J
Bioorg Med Chem; 2018 Aug; 26(15):4375-4381. PubMed ID: 30078608
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
Rao D; Li H; Ren X; Sun Y; Wen C; Zheng M; Huang H; Tang W; Xu S
Eur J Med Chem; 2021 Jul; 219():113393. PubMed ID: 33845236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
